Additionally, this article will highlight the impact of PI3K inhibitors in modulating the tumor–stromal immune crosstalk within the context of this tumor type and current challenges or limitations of targeting the PI3K pathway in PDAC. This evidence concerns the gene PIK3CA and neoplasm.